GlassScriptPhysician profile
Srikiran Pothamsetty
NPI 1821190562
$26,779.06
in general payments reported to CMS, 2019-2025
33 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $23K · 2021: $248 · 2022: $244 · 2023: $224 · 2024: $405 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $46.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.77 |
| Education | $46.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $20,000.00 | 2020 | |
| Allergan, INC. | $4,524.23 | 2019-2020 | |
| Abbvie INC. | $376.36 | 2019-2025 | |
| Janssen Biotech, INC. | $191.00 | 2019-2025 | Tremfya, Simponi, Stelara |
| Celltrion USA INC. | $165.72 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.52 | 2019-2024 | Xifaxan |
| Ardelyx, INC. | $131.39 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $102.57 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $93.35 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $91.84 | 2023-2024 | Dificid |
| Olympus America INC. | $91.04 | 2019 | |
| Redhill Biopharma INC. | $89.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.07 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $68.79 | 2022-2025 | Dupixent |
| Amgen INC. | $61.11 | 2022-2023 | Avsola, Amjevita |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $56.77 | 2019-2022 | |
| Gilead Sciences, INC. | $55.06 | 2019-2022 | |
| Covidien LP | $54.24 | 2019 | |
| Lilly USA, LLC | $50.68 | 2025 | Omvoh |
| Asd Specialty Healthcare, LLC | $49.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $38.31 | 2024 | Voquezna |
| Vivus LLC | $36.21 | 2024 | Qsymia |
| Evoke Pharma, INC. | $31.37 | 2022 | |
| Novo Nordisk INC | $30.16 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $26.47 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $23.05 | 2024 | Sutab, Suflave |
| Alnylam Pharmaceuticals INC. | $21.53 | 2025 | Givlaari |
| Genzyme Corporation | $20.91 | 2022 | |
| Celgene Corporation | $19.47 | 2021 | |
| Medtronic, INC. | $17.93 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.50 | 2022 | |
| Phadia US INC. | $12.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikiran Pothamsetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.